Global antimicrobial resistance in Gram-negative pathogens and clinical need

Current Opinion in Microbiology

Volumn 39, Issue , 2017, Pages 106-112

  Theuretzbacher, Ursula ^a  

^a Center For Anti Infective Agents Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; CROSS RESISTANCE; ENZYME SYNTHESIS; GRAM NEGATIVE BACTERIUM; HUMAN; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; PSEUDOMONAS AERUGINOSA; REVIEW; WORLD HEALTH ORGANIZATION; DRUG EFFECTS; GRAM NEGATIVE INFECTION; MICROBIOLOGY; PATHOGENICITY;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS;

EID: 85034095356     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2017.10.028     Document Type: Review

References (44)

1. World Health Organization, Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017 http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf WHO published a priority pathogens list to guide and promote antibacterial drug R&D. It based on a multi-criteria decision analysis that incorporates both evidence-based data and expert opinion.
2. Weiner, L.M., Webb, A.K., Limbago, B., Dudeck, M.A., Patel, J., Kallen, A.J., Edwards, J.R., Sievert, D.M., Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol 37 (2016), 1288–1301.
3. Vincent, J., Rello, J., Marshall, J., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302 (2009), 2323–2329.
4. Kaye, K.S., Pogue, J.M., Infections caused by resistant Gram-negative bacteria: epidemiology and management. Pharmacotherapy 35 (2015), 949–962.
5. Xu, L., Sun, X., Ma, X., Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob, 16, 2017, 18.
6. Liu, Q., Li, X., Li, W., Du, X., He, J.-Q., Tao, C., Feng, Y., Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysis. Sci Rep, 5, 2015, 11715.
7. Lemos, E.V., de la Hoz, F.P., Einarson, T.R., McGhan, W.F., Quevedo, E., Castañeda, C., Kawai, K., Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Inf 20 (2013), 416–423 Performing a systematic review and meta-analysis, the authors show an influence of carbapenem-resistance on mortality compared to carbapenem-susceptibility though heterogeneity and confounding factors require a cautious interpretation of the results.
8. Beceiro, A., Tomás, M., Bou, G., Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?. Clin Microbiol Rev 26 (2013), 185–230.
9. Thaden, J.T., Park, L.P., Maskarinec, S.A., Ruffin, F., Fowler, V.G., van Duin, D., Increased mortality associated with bloodstream infections caused by Pseudomonas aeruginosa as compared to other bacteria: results of a 13-year prospective cohort study. Antimicrob Agents Chemother, 2017.
10. Gandra, S., Mojica, N., Klein, E.Y., Ashok, A., Nerurkar, V., Kumari, M., Ramesh, U., Dey, S., Vadwai, V., Das, B.R., et al. Trends in antibiotic resistance among major bacterial pathogens isolated from blood cultures tested at a large private laboratory network in India, 2008–2014. Int J Infect Dis 50 (2016), 75–82.
11. Xu, A., Zheng, B., Xu, Y.C., Huang, Z.G., Zhong, N.S., Zhuo, C., Xu, A., Zheng, B., Xu, Y.C., Huang, Z.G., Zhong, N.S., Zhuo, C., National epidemiology of carbapenem-resistant and extensively drug-resistant Gram-negative bacteria isolated from blood samples in China in 2013. Clin Microbiol Inf 22 (2016), S1–S8.
12. Suwantarat, N., Carroll, K.C., Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia. Antimicrob Resist Infect Control, 5, 2016, 15.
13. Sader, H.S., Castanheira, M., Farrell, D.J., Flamm, R.K., Mendes, R.E., Jones, R.N., Sader, H.S., Castanheira, M., Farrell, D.J., Flamm, R.K., Mendes, R.E., Jones, R.N., Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011–2014). Int J Antimicrob Agents 48 (2016), 144–150.
14. Marimuthu, K., Venkatachalam, I., Khong, W.X., Koh, T.H., Cherng, B.P.Z., Van La, M., De, P.P., Krishnan, P.U., Tan, T.Y., Choon, R.F.K., et al. Clinical and molecular epidemiology of carbapenem-resistant enterobacteriaceae among adult inpatients in Singapore. Clin Infect Dis 64 (2017), S68–S75.
15. Satlin, M.J., Chen, L., Patel, G., Gomez-Simmonds, A., Weston, G., Kim, A.C., Seo, S.K., Rosenthal, M.E., Sperber, S.J., Jenkins, S.G., et al. Bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE): a multicenter clinical and molecular epidemiologic analysis in the nation's epicenter for CRE. Antimicrob Agents Chemother, 2017, 10.1128/AAC.02349-16.
16. Grundmann, H., Glasner, C., Albiger, B., Aanensen, D.M., Tomlinson, C.T., Andrasević, A.T., Cantón, R., Carmeli, Y., Friedrich, A.W., Giske, C.G., et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis 17 (2017), 153–163 The EuSCAPE project provides information for monitoring incidence and spread of carbapenemases and carbapenemase-producing Enterobacteriaceae in Europe. The authors describe the change in carbapenemase epidemiology in Europe.
17. Conte, V., Monaco, M., Giani, T., D'Ancona, F., Moro, M.L., Arena, F., D'Andrea, M.M., Rossolini, G.M., Pantosti, A., AR-ISS Study Group on Carbapenemase-Producing K. pneumoniae, Molecular epidemiology of KPC-producing Klebsiella pneumoniae from invasive infections in Italy: increasing diversity with predominance of the ST512 clade II sublineage. J Antimicrob Chemother 71 (2016), 3386–3391.
18. Perovic, O., Chetty, V., Antimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2015. Commun Dis Surveill Bull 14 (2016), 56–67.
19. Khalifa, H.O., Soliman, A.M., Ahmed, A.M., Shimamoto, T., Hara, T., Ikeda, M., Kuroo, Y., Kayama, S., Sugai, M., Shimamoto, T., High carbapenem resistance in clinical Gram-negative pathogens isolated in Egypt. Microbial Drug Resist, 2017, 10.1089/mdr.2015.0339.
20. Lob, S.H., Hackel, M.A., Kazmierczak, K.M., Young, K., Motyl, M.R., Karlowsky, J.A., Sahm, D.F., In vitro activity of imipenem-relebactam against Gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 – results from the SMART Global Surveillance Program. Antimicrob Agents Chemother, 2017, 10.1128/AAC.02209-16.
21. Walters, M.S., Bulens, S., Hancock, E.B., Phipps, E.C., Muleta, D., Mounsey, J., Kainer, M., Concannon, C., Dumyati, G., Bower, C., et al. Surveillance for carbapenem-resistant Pseudomonas aeruginosa at five United States sites—2015. Open Forum Infect Dis, 3, 2016, 350.
22. Sader, H.S., Huband, M.D., Castanheira, M., Flamm, R.K., Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012 to 2015) of the international network for optimal resistance monitoring program in the United States. Antimicrob Agents Chemother, 61, 2017, 10.1128/AAC.02252-16.
23. Mendes, R.E., Jones, R.N., Mendoza, M., Castanheira, M., Bell, J.M., Turnidge, J.D., Emerging markets resistance surveillance programme report for 12 Asia-Pacific nations. 9th Annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), 2013 Poster #179.
24. Rojo-Bezares, B., Cavalié, L., Dubois, D., Oswald, E., Torres, C., Sáenz, Y., Characterization of carbapenem resistance mechanisms and integrons in Pseudomonas aeruginosa strains from blood samples in a French hospital. J Med Microbiol 65 (2016), 311–319.
25. Li, J., Zou, M., Dou, Q., Hu, Y., Wang, H., Yan, Q., Liu, W.e., Characterization of clinical extensively drug-resistant Pseudomonas aeruginosa in the Hunan province of China. Ann Clin Microbiol Antimicrob, 15, 2016, 35.
26. Pragasam, A.K., Vijayakumar, S., Bakthavatchalam, Y.D., Kapil, A., Das, B.K., Ray, P., Gautam, V., Sistla, S., Parija, S.C., Walia, K., et al. Molecular characterisation of antimicrobial resistance in Pseudomonas aeruginosa and Acinetobacter baumannii during 2014 and 2015 collected across India. Indian J Med Microbiol 34 (2016), 433–441.
27. Gao, L., Lyu, Y., Li, Y., Trends in drug resistance of Acinetobacter baumannii over a 10-year period: nationwide data from the China Surveillance of Antimicrobial Resistance Program. Chinese Med J 130 (2017), 659–664.
28. OXA-23-producing carbapenem-resistant Acinetobacter baumannii in a single institution over a 65-month period in north China. BMC Infect Dis, 17, 2017, 14.
29. Ahmed, S.S., Dinc, G., Rossella, B., Alp, E., Ulu-Kilic, A., Melchers, W.J.G., Hopman, J., Voss, A., Molecular characterization of carbapenem resistant Acinetobacter baumannii and investigation of genetic diversity between local and international clones. J Pure Applied Microbiol 10 (2016), 1675–1682.
30. Vijayakumar, S., Gopi, R., Gunasekaran, P., Bharathy, M., Walia, K., Anandan, S., Veeraraghavan, B., Molecular characterization of invasive carbapenem-resistant Acinetobacter baumannii from a tertiary care hospital in South India. Inf Dis Therapy 5 (2016), 379–387.
31. Dahdouh, E., Gomez-Gil, R., Pacho, S., Mingorance, J., Daoud, Z., Suarez, M., Clonality, virulence determinants, and profiles of resistance of clinical Acinetobacter baumannii isolates obtained from a Spanish hospital. PLOS ONE, 12, 2017, e0176824.
32. Perez, F., El Chakhtoura, N.G., Papp-Wallace, K.M., Wilson, B.M., Bonomo, R.A., Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy?. Expert Opin Pharmacother 17 (2016), 761–781 This informative overview of carbapenem-resistant Enterobacteriaceae describes resistance mechanisms, epidemiology, clinical impact, treatment options as well as some new beta-lactamase inhibitor combinations.
33. Bush, K., A resurgence of beta-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents 46 (2015), 483–493 Overview of recently approved and future beta-lactamase inhibitor combinations. The review explains the different chemical classes of beta-lactamase inhibitors and compares their activities.
34. Lapuebla, A., Abdallah, M., Olafisoye, O., Cortes, C., Urban, C., Landman, D., Quale, J., Activity of imipenem with relebactam against Gram-negative pathogens from New York City. Antimicrob Agents Chemother 59 (2015), 5029–5031.
35. Castanheira, M., Rhomberg, P.R., Flamm, R.K., Jones, R.N., Effect of the beta-Lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 60 (2016), 5454–5458.
36. Sader, H.S., Castanheira, M., Huband, M., Jones, R.N., Flamm, R.K., WCK 5222 (Cefepime-Zidebactam) antimicrobial activity against clinical isolates of Gram-negative bacteria collected worldwide in 2015. Antimicrob Agents Chemother, 61, 2017, 10.1128/AAC.00072-17.
37. Livermore, D.M., Mushtaq, S., Warner, M., Vickers, A., Woodford, N., In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrob Chemother 72 (2017), 1373–1385.
38. Ito-Horiyama, T., Ishii, Y., Ito, A., Sato, T., Nakamura, R., Fukuhara, N., Tsuji, M., Yamano, Y., Yamaguchi, K., Tateda, K., Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother 60 (2016), 4384–4386.
39. Falagas, M.E., Skalidis, T., Vardakas, K.Z., Legakis, N.J., Hellenic Cefiderocol Study, G., Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. J Antimicrob Chemother, 2017, 10.1128/AAC.00072-17.
40. Almaghrabi, R., Clancy, C.J., Doi, Y., Hao, B., Chen, L., Shields, R.K., Press, E.G., Iovine, N.M., Townsend, B.M., Wagener, M.M., et al. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother 58 (2014), 4443–4451.
41. Wangkheimayum, J., Paul, D., Dhar, D., Nepram, R., Chetri, S., Bhowmik, D., Chakravarty, A., Bhattacharjee, A., Occurrence of acquired 16s methyltransferase mediated aminoglycoside resistance in clinical isolates of Enterobacteriaceae within a tertiary referral hospital of northeast India. Antimicrob Agents Chemother, 2017, 10.1128/AAC.01037-16.
42. Livermore, D.M., Mushtaq, S., Warner, M., Woodford, N., In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother 60 (2016), 3840–3844.
43. Scorciapino, M.A., Rinaldi, A.C., Antimicrobial peptidomimetics: reinterpreting nature to deliver innovative therapeutics. Front Immunol, 3, 2012, 171.
44. DiGiandomenico, A., Keller, A.E., Gao, C., Rainey, G.J., Warrener, P., Camara, M.M., Bonnell, J., Fleming, R., Bezabeh, B., Dimasi, N., et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med, 6, 2014, 262ra155.